Quantitative MRI for characterizing heart failure with preserved ejection fraction
定量 MRI 用于表征射血分数保留的心力衰竭
基本信息
- 批准号:9311349
- 负责人:
- 金额:$ 53.86万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-05-15 至 2021-04-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAdvanced DevelopmentAnimal ModelAnimalsAreaBiological MarkersBloodBreathingCardiacCardiovascular systemCessation of lifeCollaborationsComplementConflict (Psychology)DataDevelopmentDiagnosisDiagnosticDiastoleDiseaseDyspneaEFRACEconomic BurdenEpidemicEventEvolutionFailureFamily suidaeFibrosisFunctional disorderFutureHeartHeart DiseasesHeart failureHumanKnowledgeMagnetic Resonance ImagingMeasurementMeasuresMethodsMicrospheresMicrovascular DysfunctionModelingMonitorMotionMyocardial perfusionMyocardial tissuePatientsPerformancePerfusionPharmacotherapyPhenotypePhysiologic pulsePlayPopulationPositron-Emission TomographyPrognostic MarkerPublic HealthRadialRoleScanningSliceSymptomsSyndromeSystoleTechniquesTechnologyTestingTimeUtahValidationbasecoronary fibrosisdesigndisabilityeffective therapyhemodynamicsimaging approachimprovedinsightinstrumentmortalityperfusion imagingprogramsreconstructionresearch clinical testingserial imagingsuccesstemporal measurementtooltreatment response
项目摘要
Heart failure with preserved ejection fraction (HFpEF) is currently being studied intensely as several
large trials of drug therapies have failed to benefit patients. Better characterization of these patients is
important, and there are open questions regarding microvascular disease and remodeling in the
HFpEF population. New MRI methods could be ideal to better characterize and understand HFpEF
and its response to treatments. This project seeks to develop, evaluate and apply new MRI methods
for high-end perfusion imaging. These methods will estimate endo/epi ratios across the cardiac cycle
in free-breathing studies, which will be used along with other new MRI measurements and blood
biomarkers to provide new information about microvascular disease. This is of particular value for
assessing HFpEF.
The aims and methods of this project are to (1) develop and compare new 2D radial simultaneous
multi-slice (SMS) and 3D stack-of-stars (SoS) acquisitions and reconstruction methods for
quantitative perfusion measurements. (2) To validate the new 2D radial SMS and 3D SoS free-
breathing methods in an animal model of HFpEF, and in humans to further characterize the new
methods by comparison to a more standard MRI method and to dynamic PET. (3) To use the
methods along with fibrosis quantitation and other MRI measures to characterize perfusion and
fibrosis changes over time in patients with HFpEF. This will give more insight into non-invasive MRI-
based perfusion and fibrosis biomarkers and how they complement other biomarkers and give insight
into different subtypes of HFpEF.
The relevance to public health is that HFpEF is a leading cause of disability and death and no
effective treatment is known. The development and use of accurate and repeatable measurements of
perfusion and their combination with fibrosis quantitation will lead to accelerated evaluation of clinical
therapies. The project will also provide new tools and knowledge for better management of patients
with HFpEF. The proposed approach will be extended to better understand a range of cardiac
diseases.
射血分数正常的心力衰竭(HFpEF)目前正在进行深入研究,
大规模的药物治疗试验未能使患者受益。
重要的是,关于微血管疾病和重塑,
新的MRI方法可能是更好地表征和理解HFpEF的理想方法
该项目旨在开发、评估和应用新的MRI方法,
这些方法将估计整个心动周期内的endo/epi比值,
在自由呼吸研究中,这将与其他新的MRI测量和血液分析一起沿着使用。
生物标志物提供有关微血管疾病的新信息。这对于
评估HFpEF。
本课题的目的和方法是:(1)开发和比较新的二维径向同步
多层面(SMS)和3D叠层恒星(SoS)采集和重建方法,
(2)验证新的2D径向SMS和3D SoS自由血流灌注模型的有效性
在HFpEF动物模型和人类中使用呼吸方法,以进一步表征新的
方法通过比较更标准的MRI方法和动态PET。(3)使用
方法沿着纤维化定量和其他MRI测量来表征灌注,
HFpEF患者的纤维化随时间变化。这将使我们更深入地了解非侵入性MRI-MRI
基于灌注和纤维化的生物标志物,以及它们如何补充其他生物标志物,
不同亚型的HFpEF。
与公共卫生的相关性是HFpEF是残疾和死亡的主要原因,
有效的治疗是已知的。开发和使用准确和可重复的测量,
灌注及其与纤维化定量的结合将加速临床评估
该项目还将为更好地管理患者提供新的工具和知识。
所提出的方法将被扩展到更好地了解一系列心脏
疾病
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
EDWARD VR DIBELLA其他文献
EDWARD VR DIBELLA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('EDWARD VR DIBELLA', 18)}}的其他基金
Improved Imaging of Fibrosis in Atrial Fibrillation
改善心房颤动纤维化的成像
- 批准号:
10576920 - 财政年份:2022
- 资助金额:
$ 53.86万 - 项目类别:
Improved Imaging of Fibrosis in Atrial Fibrillation
改善心房颤动纤维化的成像
- 批准号:
10392232 - 财政年份:2022
- 资助金额:
$ 53.86万 - 项目类别:
Quantitative cardiac MRI perfusion for longitudinal studies
用于纵向研究的定量心脏 MRI 灌注
- 批准号:
8705575 - 财政年份:2012
- 资助金额:
$ 53.86万 - 项目类别:
Quantitative cardiac MRI perfusion for longitudinal studies
用于纵向研究的定量心脏 MRI 灌注
- 批准号:
8373623 - 财政年份:2012
- 资助金额:
$ 53.86万 - 项目类别:
Quantitative cardiac MRI perfusion for longitudinal studies
用于纵向研究的定量心脏 MRI 灌注
- 批准号:
8525433 - 财政年份:2012
- 资助金额:
$ 53.86万 - 项目类别:
Compressed Sensing with Motion Models for MRI of Late Gadolinium Enhancement
用于后期钆增强 MRI 的运动模型压缩感知
- 批准号:
8319301 - 财政年份:2011
- 资助金额:
$ 53.86万 - 项目类别:
Compressed Sensing with Motion Models for MRI of Late Gadolinium Enhancement
用于后期钆增强 MRI 的运动模型压缩感知
- 批准号:
8179726 - 财政年份:2011
- 资助金额:
$ 53.86万 - 项目类别:
相似海外基金
ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
用于 Pansarbecovirus 疫苗的 LQ A 脂质体含皂苷佐剂的先进开发
- 批准号:
10935820 - 财政年份:2023
- 资助金额:
$ 53.86万 - 项目类别:
ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"
BBT-059 的先进开发,作为辐射医学对策,可在暴露后 48 小时内进行给药”
- 批准号:
10932514 - 财政年份:2023
- 资助金额:
$ 53.86万 - 项目类别:
Advanced Development of a Combined Shigella-ETEC Vaccine
志贺氏菌-ETEC 联合疫苗的先进开发
- 批准号:
10704845 - 财政年份:2023
- 资助金额:
$ 53.86万 - 项目类别:
Advanced development of composite gene delivery and CAR engineering systems
复合基因递送和CAR工程系统的先进开发
- 批准号:
10709085 - 财政年份:2023
- 资助金额:
$ 53.86万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10409385 - 财政年份:2022
- 资助金额:
$ 53.86万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10710595 - 财政年份:2022
- 资助金额:
$ 53.86万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10630975 - 财政年份:2022
- 资助金额:
$ 53.86万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
金黄色葡萄球菌感染候选疫苗的高级开发
- 批准号:
10710588 - 财政年份:2022
- 资助金额:
$ 53.86万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10788051 - 财政年份:2022
- 资助金额:
$ 53.86万 - 项目类别: